Erste Asset Management GmbH Invests $360,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Erste Asset Management GmbH bought a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $360,000. Erste Asset Management GmbH owned 0.07% of EyePoint Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Swiss National Bank lifted its stake in shares of EyePoint Pharmaceuticals by 3.5% in the fourth quarter. Swiss National Bank now owns 100,000 shares of the company’s stock valued at $745,000 after purchasing an additional 3,400 shares during the period. China Universal Asset Management Co. Ltd. raised its position in EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after acquiring an additional 4,179 shares during the last quarter. Cyndeo Wealth Partners LLC raised its position in EyePoint Pharmaceuticals by 35.5% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company’s stock worth $127,000 after acquiring an additional 4,450 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in EyePoint Pharmaceuticals by 5.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after acquiring an additional 7,967 shares during the last quarter. Finally, AlphaQuest LLC raised its position in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock worth $73,000 after acquiring an additional 9,670 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Chardan Capital restated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday. Finally, Citigroup started coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price for the company. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Price Performance

Shares of NASDAQ EYPT opened at $6.52 on Friday. The company has a market cap of $448.11 million, a PE ratio of -3.26 and a beta of 1.41. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.54 and a 12 month high of $23.97. The company has a 50-day simple moving average of $7.19 and a 200-day simple moving average of $8.39.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million. On average, analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.